This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pinthus, J. H. Articles by Eshhar, Z. Search for Related Content PubMed PubMed Citation Articles by Pinthus, J. H. Articles by Eshhar, Z.

WISH-PC2: A Unique Xenograft Model of Human Prostatic Small Cell Carcinoma¹

Department of Immunology [J. H. P., T. W., D. G. S., Z. E.] and The Experimental Animal Center [A. H.], The Weizmann Institute of Science, Rehovot 76100, Israel; Department of Urology [J. H. P., J. R.], Sheba Medical Center, Tel-Hashomer 52621 Israel; and Departments of Pathology [J. W. S.] and Urology [A. B.], UCLA School of Medicine, Los Angeles, California 90095

Prostatic small cell carcinoma is an aggressive subtype of prostate cancer that usually appears as a progression of the original adenocarcinoma. We describe here the WISH-PC2, a novel neuroendocrine xenograft of small cell carcinoma of the prostate. This xenograft was established from a poorly differentiated prostate adenocarcinoma and is serially transplanted in immune-compromised mice where it grows within the prostate, liver, and bone, inducing osteolytic lesions with foci of osteoblastic activity. It secretes to the mouse Chromogranin A and expresses prostate plasma carcinoma tumor antigen-1, six-transmembrane epithelial antigen of the prostate, and members of the Erb-B receptor family. It does not express prostate-specific antigen, prostate stem cell antigen, prostate-specific membrane antigen, and androgen receptor, and it grows independently of androgen. Altogether, WISH-PC2 provides an unlimited source in which to study the involvement of neuroendocrine cells in the progression of prostatic adenocarcinoma and can serve as a novel model for the testing of new therapeutic strategies for prostatic small cell carcinoma.

This article has been cited by other articles:

				T.-C. Yuan, S. Veeramani, and M.-F. Lin Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells Endocr. Relat. Cancer, September 1, 2007; 14(3): 531 - 547. [Abstract] [Full Text] [PDF]

				B. S. Kochupurakkal, D. Harari, A. Di-Segni, G. Maik-Rachline, L. Lyass, G. Gur, G. Kerber, A. Citri, S. Lavi, R. Eilam, et al. Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity J. Biol. Chem., March 4, 2005; 280(9): 8503 - 8512. [Abstract] [Full Text] [PDF]

				D. R. Gray, W. J. Huss, J. M. Yau, L. E. Durham, E. S. Werdin, W. K. Funkhouser Jr., and G. J. Smith Short-Term Human Prostate Primary Xenografts: An in Vivo Model of Human Prostate Cancer Vasculature and Angiogenesis Cancer Res., March 1, 2004; 64(5): 1712 - 1721. [Abstract] [Full Text] [PDF]

				M. Goldenberg-Furmanov, I. Stein, E. Pikarsky, H. Rubin, S. Kasem, M. Wygoda, I. Weinstein, H. Reuveni, and S. A. Ben-Sasson Lyn Is a Target Gene for Prostate Cancer: Sequence-Based Inhibition Induces Regression of Human Tumor Xenografts Cancer Res., February 1, 2004; 64(3): 1058 - 1066. [Abstract] [Full Text] [PDF]

				J. H. Pinthus, T. Waks, K. Kaufman-Francis, D. G. Schindler, A. Harmelin, H. Kanety, J. Ramon, and Z. Eshhar Immuno-Gene Therapy of Established Prostate Tumors Using Chimeric Receptor-redirected Human Lymphocytes Cancer Res., May 15, 2003; 63(10): 2470 - 2476. [Abstract] [Full Text] [PDF]

				L. D. True, K. Buhler, J. Quinn, E. Williams, P. S. Nelson, N. Clegg, J. A. Macoska, T. Norwood, A. Liu, W. Ellis, et al. A Neuroendocrine/Small Cell Prostate Carcinoma Xenograft--LuCaP 49 Am. J. Pathol., August 1, 2002; 161(2): 705 - 715. [Abstract] [Full Text] [PDF]